Literature DB >> 1690735

Characterization of reverse transcriptase from feline immunodeficiency virus.

T W North1, R C Cronn, K M Remington, R T Tandberg, R C Judd.   

Abstract

Reverse transcriptase has been purified from feline immunodeficiency virus (FIV) by DEAE-cellulose and phosphocellulose chromatography. The purified enzyme consists of a single protein with a Mr of 67,000. When proteolysis is not minimized during purification, a fragment of Mr 54,000 is also observed. This is similar to the reverse transcriptase from human immunodeficiency virus type 1 (HIV), which consists of a polypeptide of Mr 66,000; when proteolysis is not minimized during purification, a fragment of Mr 51,000 is also observed. In direct comparisons, the FIV reverse transcriptase is very similar to the HIV reverse transcriptase in template specificity and requirements for Mg2+. In contrast to these similarities, the FIV and HIV reverse transcriptases are substantially different in primary sequence, as determined by peptide mapping.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690735

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Insertion of a peptide from MuLV RT into the connection subdomain of HIV-1 RT results in a functionally active chimeric enzyme in monomeric conformation.

Authors:  P K Pandey; N Kaushik; T T Talele; P N Yadav; V N Pandey
Journal:  Mol Cell Biochem       Date:  2001-09       Impact factor: 3.396

2.  A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides.

Authors:  R A Smith; K M Remington; R M Lloyd; R F Schinazi; T W North
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine.

Authors:  Y Q Zhu; K M Remington; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

4.  Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine.

Authors:  J M Gobert; K M Remington; Y Q Zhu; T W North
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

5.  Feline immunodeficiency virus reverse transcriptase: expression, functional characterization, and reconstitution of the 66- and 51-kilodalton subunits.

Authors:  M Amacker; M Hottiger; U Hübscher
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

Review 6.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

7.  Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases.

Authors:  E J Arts; S R Stetor; X Li; J W Rausch; K J Howard; B Ehresmann; T W North; B M Wöhrl; R S Goody; M A Wainberg; S F Grice
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

8.  Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine.

Authors:  K M Remington; B Chesebro; K Wehrly; N C Pedersen; T W North
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Evidence for CD8+ antiviral activity in cats infected with feline immunodeficiency virus.

Authors:  C R Jeng; R V English; T Childers; M B Tompkins; W A Tompkins
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine.

Authors:  H K Medlin; Y Q Zhu; K M Remington; T R Phillips; T W North
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.